PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9262988-5 1997 Incubation with IL1+IL3+SCF caused an increase (fold expansion) in committed (28.6 +/- 8.1), immature (5.8 +/- 1.8), and primitive progenitors (4.1 +/- 0.8) among control CB MNC compared to a decrease in committed progenitors (0 +/- 0) but an increase in both immature (8.4 +/- 4.8) and primitive progenitors (7 +/- 2.9) among 5-FU resistant CB MNC. Fluorouracil 327-331 interleukin 1 alpha Homo sapiens 16-19 9238541-0 1997 Effect of 5-fluorouracil on interleukin-1 and interleukin-2 receptor expression. Fluorouracil 10-24 interleukin 1 alpha Homo sapiens 28-41 9238541-1 1997 We have studied the effect of anticancer drug 5-fluorouracil on the expression of human Interleukin-1 and Interleukin-2 receptor. Fluorouracil 46-60 interleukin 1 alpha Homo sapiens 88-101 9238541-2 1997 In this report, we show that 5-Fluorouracil increases the Interleukin-1 expression upto 2.66 folds without significantly affecting the levels of surface expression of p55 IL-2 receptor on human Peripheral blood mononuclear cells, CD4 and CD8 T cells. Fluorouracil 29-43 interleukin 1 alpha Homo sapiens 58-71 9238541-5 1997 Taken together, 5-fluorouracil differentially affects the expression of Interleukin-1, Interferon-gamma and Interleukin-2 receptor. Fluorouracil 16-30 interleukin 1 alpha Homo sapiens 72-85 15001844-6 2004 However, Neu5Ac-Gal-IL-1alpha exhibited comparable activity to IL-1alpha in improvement of the recovery of peripheral white blood cells from myelosuppression in 5-fluorouracil-treated mice. Fluorouracil 161-175 interleukin 1 alpha Homo sapiens 20-29 7534710-2 1995 We found a significant increase in the proportion of CD34+ cells in the PBSC fraction resistant to 25 micrograms/mL 5-FU after 7-day incubation with IL-1 plus IL-3 plus SCF as compared with the untreated fraction (p = 0.011). Fluorouracil 116-120 interleukin 1 alpha Homo sapiens 149-153 9143391-1 1997 Interleukin-1 alpha (IL-1 alpha) is myeloprotective in a variety of animal models of cancer chemotherapy and is similarly beneficial in adults treated with carboplatin, 5-fluorouracil, and after autologous bone marrow transplantation. Fluorouracil 169-183 interleukin 1 alpha Homo sapiens 0-19 9143391-1 1997 Interleukin-1 alpha (IL-1 alpha) is myeloprotective in a variety of animal models of cancer chemotherapy and is similarly beneficial in adults treated with carboplatin, 5-fluorouracil, and after autologous bone marrow transplantation. Fluorouracil 169-183 interleukin 1 alpha Homo sapiens 21-31 7534710-3 1995 We also showed that 5-FU-resistant PBSC have a greater capacity for expansion of IL-1/IL-3/SCF-responsive immature progenitors (p = 0.05), amplification of IL-3 plus GM-CSF responsive progenitors (p = 0.01), and production of committed single growth factor-responsive (granulocyte-macrophage colony-stimulating factor [GM-CSF]) precursors (p = 0.01) than the untreated PBSC. Fluorouracil 20-24 interleukin 1 alpha Homo sapiens 81-85 7787251-1 1994 Recombinant human interleukin-1 alpha (rIL-1 alpha), at concentrations that were not growth-inhibitory when given alone (100-10,000 U/ml), enhanced the growth inhibition resulting from a 72-h fluorouracil (FUra) exposure in HCT116 colon cancer cells. Fluorouracil 192-204 interleukin 1 alpha Homo sapiens 18-37 7522897-2 1994 The resulting 5-FU-resistant cells were evaluated for (1) the production of GM-CSF-responsive clonogenic elements (CE), (2) the production of IL-3+GM-CSF-responsive CE, and (3) their self-renewal capacity (production of IL-1+IL-3+SCF-responsive CE). Fluorouracil 14-18 interleukin 1 alpha Homo sapiens 220-229 7787251-1 1994 Recombinant human interleukin-1 alpha (rIL-1 alpha), at concentrations that were not growth-inhibitory when given alone (100-10,000 U/ml), enhanced the growth inhibition resulting from a 72-h fluorouracil (FUra) exposure in HCT116 colon cancer cells. Fluorouracil 206-210 interleukin 1 alpha Homo sapiens 18-37 8142915-1 1994 In vivo, recombinant human interleukin 1 alpha (rHuIL-1 alpha) + recombinant human macrophage colony-stimulating factor (rHuM-CSF) (IL-1 + M-CSF) effectively serves as a rescue agent for myelosuppression by enhancing the recovery of hematopoietic stem cell (HSC) subpopulations following treatment with 5-fluorouracil (5-FU). Fluorouracil 303-317 interleukin 1 alpha Homo sapiens 27-46 8142915-1 1994 In vivo, recombinant human interleukin 1 alpha (rHuIL-1 alpha) + recombinant human macrophage colony-stimulating factor (rHuM-CSF) (IL-1 + M-CSF) effectively serves as a rescue agent for myelosuppression by enhancing the recovery of hematopoietic stem cell (HSC) subpopulations following treatment with 5-fluorouracil (5-FU). Fluorouracil 319-323 interleukin 1 alpha Homo sapiens 27-46 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. Fluorouracil 258-272 interleukin 1 alpha Homo sapiens 90-109 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. Fluorouracil 258-272 interleukin 1 alpha Homo sapiens 111-121 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. Fluorouracil 274-280 interleukin 1 alpha Homo sapiens 90-109 8339382-1 1993 The present study shows that various cytokines such as tumor necrosis factor (TNF alpha), interleukin-1 alpha (IL-1 alpha), and interferon-gamma (IFN gamma) make tumor cells much more susceptible to the cytostatic 5"-deoxy-5-fluorouridine (5"-dFUrd) than to 5-fluorouracil (5-FUra) and other cytostatics. Fluorouracil 274-280 interleukin 1 alpha Homo sapiens 111-121 1638519-2 1992 The results presented herein demonstrate that the pretreatment of mice with recombinant human interleukin 1 alpha (rhIL-1 alpha) protects mice from the lethal effects of several myelotoxic chemotherapeutic drugs, including 5-fluorouracil (5FUra), cyclophosphamide, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Fluorouracil 223-237 interleukin 1 alpha Homo sapiens 94-113 1638519-2 1992 The results presented herein demonstrate that the pretreatment of mice with recombinant human interleukin 1 alpha (rhIL-1 alpha) protects mice from the lethal effects of several myelotoxic chemotherapeutic drugs, including 5-fluorouracil (5FUra), cyclophosphamide, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Fluorouracil 239-244 interleukin 1 alpha Homo sapiens 94-113 2060021-1 1991 In this study, we investigated the effect of human recombinant interleukin-1 alpha (IL-1 alpha) on antigen-presenting cell (APC) activity of spleen cells in mice treated with 5-fluorouracil (5-FU). Fluorouracil 175-189 interleukin 1 alpha Homo sapiens 84-94 1587305-1 1992 The ability of highly purified, recombinant human macrophage colony-stimulating factor (M-CSF) and recombinant human interleukin 1 alpha (IL-1) to rescue hematopoietic activity from the myelosuppressive effects of 5-fluorouracil (5-FU) was investigated in the C57Bl/6 mouse. Fluorouracil 214-228 interleukin 1 alpha Homo sapiens 138-142 1587305-1 1992 The ability of highly purified, recombinant human macrophage colony-stimulating factor (M-CSF) and recombinant human interleukin 1 alpha (IL-1) to rescue hematopoietic activity from the myelosuppressive effects of 5-fluorouracil (5-FU) was investigated in the C57Bl/6 mouse. Fluorouracil 230-234 interleukin 1 alpha Homo sapiens 138-142 1587305-2 1992 IL-1 (q24 h x 4) stimulated granulopoietic recovery in the 5-FU-treated animals and reduced the period of severe neutropenia associated with this drug by 7 days. Fluorouracil 59-63 interleukin 1 alpha Homo sapiens 0-4 1587305-5 1992 Unexpectedly, the combination of IL-1 plus M-CSF (q24 h, days 1-4) followed by M-CSF (q24 h, days 5-14) resulted in a more than additive stimulation of progenitor recovery in both the marrow and the spleen that was observed as early as day 3 following 5-FU treatment. Fluorouracil 252-256 interleukin 1 alpha Homo sapiens 33-37 1587305-6 1992 Furthermore, in the absence of protracted M-CSF administration on days 5-14, the 4-day rescue with a combination of IL-1 plus M-CSF also resulted in a more than additive effect on the recovery from 5-FU-induced neutropenia. Fluorouracil 198-202 interleukin 1 alpha Homo sapiens 116-120 1587305-7 1992 Collectively, these observations demonstrated that IL-1 and M-CSF can interact synergistically to stimulate granulopoietic recovery in the 5-FU-treated animal. Fluorouracil 139-143 interleukin 1 alpha Homo sapiens 51-55 2060021-1 1991 In this study, we investigated the effect of human recombinant interleukin-1 alpha (IL-1 alpha) on antigen-presenting cell (APC) activity of spleen cells in mice treated with 5-fluorouracil (5-FU). Fluorouracil 191-195 interleukin 1 alpha Homo sapiens 63-82 2258610-2 1990 In this study, recombinant human IL-1 alpha (rhIL-1 alpha) was used to protect normal and tumor-bearing BALB/c mice from the acute toxicity caused by lethal doses of cyclophosphamide (Cy) and 5-fluorouracil. Fluorouracil 192-206 interleukin 1 alpha Homo sapiens 33-43 35634282-9 2022 The combination of 5-FU with ICB augmented an inflammatory tumor microenvironment with markedly increased CD8+ T cell activation and upregulation of IFNgamma, TNFalpha and IL-1beta signaling. Fluorouracil 19-23 interleukin 1 alpha Homo sapiens 172-180 34452150-3 2021 5-FU activity leads to caspase-1 activation, secretion and maturation of interleukins (IL)-1, IL-18 and reactive oxygen species (ROS) generation. Fluorouracil 0-4 interleukin 1 alpha Homo sapiens 73-92 35634282-10 2022 The effective anti-tumor immune response of 5-FU chemo-immunotherapy was dependent on CD8+ T cells but was unaffected when TNFalpha or IL-1beta cytokine signaling pathways were blocked. Fluorouracil 44-48 interleukin 1 alpha Homo sapiens 135-143 35448938-6 2022 In our results, the three SCFAs could inhibit ROS expressions, NLRP3, Caspase-1, IL-1beta, IL-6, IL-18, Beclin-1 and LC3-II, when induced by 5-FU. Fluorouracil 141-145 interleukin 1 alpha Homo sapiens 81-89 3499607-3 1987 When bone marrow cells from 5-fluorouracil-treated mice were cultured in suspension for 7 days with recombinant human IL-1 alpha and/or G-CSF, it was found that the two factors synergized to enhance recovery of myelopoietic cells and colony-forming cells of both high and low proliferative potential. Fluorouracil 28-42 interleukin 1 alpha Homo sapiens 118-128 3264195-1 1988 Serial observations of blast cell colony development from spleen cells of mice treated with 5-fluorouracil (5-FU) four days earlier revealed that either form of human interleukin-1 (IL-1 alpha or IL-1 beta) hastens the emergence of interleukin-3 (IL-3)-dependent blast cell colonies. Fluorouracil 92-106 interleukin 1 alpha Homo sapiens 167-180 3264195-1 1988 Serial observations of blast cell colony development from spleen cells of mice treated with 5-fluorouracil (5-FU) four days earlier revealed that either form of human interleukin-1 (IL-1 alpha or IL-1 beta) hastens the emergence of interleukin-3 (IL-3)-dependent blast cell colonies. Fluorouracil 92-106 interleukin 1 alpha Homo sapiens 182-192 3264195-1 1988 Serial observations of blast cell colony development from spleen cells of mice treated with 5-fluorouracil (5-FU) four days earlier revealed that either form of human interleukin-1 (IL-1 alpha or IL-1 beta) hastens the emergence of interleukin-3 (IL-3)-dependent blast cell colonies. Fluorouracil 108-112 interleukin 1 alpha Homo sapiens 167-180 2685478-1 1989 Injection of a single dose of recombinant human interleukin-1 alpha (r-hu-IL-1 alpha) into mice 24 hr after 5-fluorouracil (FU) treatment resulted in an increased rate of recovery of three types of colony-forming cells (CFCs) in the bone marrow. Fluorouracil 108-122 interleukin 1 alpha Homo sapiens 48-67 3499607-6 1987 Daily administration of recombinant human G-CSF or recombinant human IL-1 alpha accelerated recovery of stem cells, progenitor cells, and blood neutrophils by up to 4 days in 5-fluorouracil-treated C3H/HeJ and B6D2F1 mice. Fluorouracil 175-189 interleukin 1 alpha Homo sapiens 69-79 31120863-7 2019 We found that DKO HSCs and progenitors have impaired sensing of inflammatory signals ex vivo, and that levels of IL1-beta and MIG are higher in the bone marrow after LPS than after 5-FU administration. Fluorouracil 181-185 interleukin 1 alpha Homo sapiens 113-121 30583087-4 2019 In this study we have shown that the increase in exogenous IL-1alpha signaling increases chemosensitivity of both chemosensitive and chemoresistant colorectal cancer cell lines, treated with a widely used cytotoxic antimetabolite 5-fluorouracil (5-FU). Fluorouracil 230-244 interleukin 1 alpha Homo sapiens 59-68 30583087-4 2019 In this study we have shown that the increase in exogenous IL-1alpha signaling increases chemosensitivity of both chemosensitive and chemoresistant colorectal cancer cell lines, treated with a widely used cytotoxic antimetabolite 5-fluorouracil (5-FU). Fluorouracil 246-250 interleukin 1 alpha Homo sapiens 59-68